Key Takeaways
- • Lee Equity Partners has completed a strategic investment in Marwood Group, a healthcare-focused advisory and consulting firm, with financial terms undisclosed; the partnership is designed to fund acquisitions, senior hires, and capability expansion.
- • Chris Librizzi, formerly head of U.S. strategy consulting at EY-Parthenon, has been appointed Chief Executive Officer of Marwood Group, bringing five years of experience building and leading strategy consulting operations at EY.
- • Richard Jeanneret, a 20-year EY veteran and longtime board member, joins as Executive Chairman; his background includes advisory work with corporate boards, multinational enterprises, and private equity firms on M&A transactions.
- • Marwood's existing leadership—President Walt Breakell, Chief Revenue Officer Lee Alvarez, and Chief Product Officer Martin Sobel—remain in place, ensuring operational continuity during the transition.
- • The partnership targets expansion into private equity transaction advisory services alongside entry into adjacent healthcare segments including hospitals, payors, and life sciences companies.
Summary
Marwood Group, a market-leading healthcare advisory and consulting firm, has secured a strategic investment from Lee Equity Partners to accelerate growth through acquisitions, senior recruitment, and capability development. While financial terms were not disclosed, the partnership represents a significant backing for the firm's next phase of expansion and market positioning.
The leadership restructuring brings substantial healthcare and professional services expertise to Marwood's top tier. Chris Librizzi assumes the Chief Executive Officer role after spending five years at EY-Parthenon leading the firm's U.S. strategy consulting business. Prior to that role, Librizzi built and directed EY's corporate strategy function and served on the company's U.S. Board and Executive Committee, positioning him with deep institutional knowledge of enterprise advisory operations. Richard Jeanneret joins as Executive Chairman with approximately 20 years of EY experience, including extended tenure as one of the firm's longest-serving board members. Jeanneret's background encompasses advisory services to corporate boards and multinational companies, as well as transaction support for private equity sponsors and M&A execution.
Marwood has maintained operational continuity by retaining existing senior leadership. Walt Breakell continues as President and board member, Lee Alvarez remains Chief Revenue Officer, and Martin Sobel continues as Chief Product Officer. This stability underscores a measured approach to the strategic investment, focusing on augmenting rather than dismantling existing management structures.
The partnership explicitly targets expansion of Marwood's advisory footprint within private equity transaction cycles—a high-value advisory segment—alongside entry into adjacent healthcare verticals including hospital systems, insurance payors, and life sciences companies. This diversification strategy leverages Marwood's established expertise in healthcare policy and regulatory frameworks while broadening its addressable market and client segments.
The leadership restructuring brings substantial healthcare and professional services expertise to Marwood's top tier. Chris Librizzi assumes the Chief Executive Officer role after spending five years at EY-Parthenon leading the firm's U.S. strategy consulting business. Prior to that role, Librizzi built and directed EY's corporate strategy function and served on the company's U.S. Board and Executive Committee, positioning him with deep institutional knowledge of enterprise advisory operations. Richard Jeanneret joins as Executive Chairman with approximately 20 years of EY experience, including extended tenure as one of the firm's longest-serving board members. Jeanneret's background encompasses advisory services to corporate boards and multinational companies, as well as transaction support for private equity sponsors and M&A execution.
Marwood has maintained operational continuity by retaining existing senior leadership. Walt Breakell continues as President and board member, Lee Alvarez remains Chief Revenue Officer, and Martin Sobel continues as Chief Product Officer. This stability underscores a measured approach to the strategic investment, focusing on augmenting rather than dismantling existing management structures.
The partnership explicitly targets expansion of Marwood's advisory footprint within private equity transaction cycles—a high-value advisory segment—alongside entry into adjacent healthcare verticals including hospital systems, insurance payors, and life sciences companies. This diversification strategy leverages Marwood's established expertise in healthcare policy and regulatory frameworks while broadening its addressable market and client segments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.